The results supplemented the existing data concerning the relationship of ARID5B and MTX, an anticancer agent widely used in the risk-adjusted therapy of childhood ALL (Moricke et al., 2008). The gene discussed is ARID5B; the disease is acute lymphoblastic leukemia.